1
|
Management of Advanced and Metastatic Prostate Cancer: A Need for a Sub-Saharan Guideline. JOURNAL OF ONCOLOGY 2019; 2019:1785428. [PMID: 31885569 PMCID: PMC6915139 DOI: 10.1155/2019/1785428] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Received: 08/03/2019] [Revised: 11/13/2019] [Accepted: 11/21/2019] [Indexed: 12/12/2022]
Abstract
The estimated incidence rate of prostate cancer in Africa was 22.0/100,000 in 2016. The International Agency for Research on Cancer (IARC) has cited prostate cancer as a growing health threat in Africa with approximated 28,006 deaths in 2010 and estimated 57,048 deaths in 2030. The exact incidence of advanced and metastatic prostate cancer is not known in sub-Saharan Africa. Hospital-based reports from the region have shown a rising trend with most patients presenting with advanced or metastatic disease. The management of advanced and metastatic prostate cancer is challenging. The available international guidelines may not be cost-effective for an African population. The most efficient approach in the region has been surgical castration by bilateral orchidectomy or pulpectomy. Medical androgen deprivation therapy is expensive and may not be available. Patients with metastatic castrate-resistant prostate cancer tend to be palliated due to the absence or cost of chemotherapy or second-line androgen deprivation therapy in most of Africa. A cost-effective guideline for developing nations to address the rising burden of advanced prostate cancer is warranted at this moment.
Collapse
|
2
|
Ditonno P, Battaglia M, Selvaggi FP. Adjuvant Hormone Therapy after Radical Prostatectomy: Indications and Results. TUMORI JOURNAL 2018; 83:567-75. [PMID: 9226023 DOI: 10.1177/030089169708300219] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Despite recent advances in staging modalities, nearly 30–40% of patients undergoing radical prostatectomy for clinically localized prostate cancer have residual disease. In these cases, one or more of the following conditions may be present: extracapsular disease, positive margins, invasion of the seminal vesicles, lymph node metastases or the postoperative persistence of PSA values above the biological threshold. The optimal management for residual prostate cancer remains controversial and in this setting adjuvant therapy could be appropriate. In the present review we examine the conditions in which hormonal adjuvant therapy can be indicated and the results available from retrospective or non-randomized studies. From the data in the literature and in the absence of randomized prospective studies, prudent conclusions could be drawn on the efficacy of adjuvant hormonal therapy. In cases of small volume, low grade (Gleason score «7) prostate cancer in stage C or D1, radical surgery coupled with adjuvant hormonal therapy leads to survival rates in stage C similar to those in the intraprostatic stage, and in stage D1 with minimal lymph involvement, seems to delay clinical development of metastases. Finally, the quality of life associated with adjuvant therapy and the drug regimens available for this therapy are reviewed.
Collapse
Affiliation(s)
- P Ditonno
- Cattedra di Urologia R, Università degli Studi di Bari, Italy
| | | | | |
Collapse
|
3
|
Abstract
BACKGROUND Due to an inverse stage migration, the proportion of patients with more aggressive and locally advanced prostate cancer (PCa) has increased over the last few years. The natural history in these patients shows a higher risk of local complications and worse oncologic outcome. OBJECTIVES To analyze the impact of radical prostatectomy (RP) in patients with locally advanced PCa. MATERIALS AND METHODS A review of the literature was performed using PubMed and MEDLINE databases focusing on articles addressing locally advanced PCa. RESULTS Current guidelines recommend local therapy in patients with locally advanced PCa among other treatment options. Thereby no strong evidence favoring radiotherapy or RP is present. Compared to patients without local treatment, RP may improve oncologic outcome and decrease the risk of local complications. Due to more difficult surgery and an increased need of multimodal therapy, higher perioperative morbidity and worse functional outcomes compared to patients with localized PCa are reported. No reliable prospective data indicating a widespread use of neoadjuvant treatment exists. Indication for further adjuvant or salvage therapies depends on pathologic results and postoperative course. CONCLUSIONS RP is one of the treatment options with good long-term results which can be offered to patients with locally advanced PCa. Nevertheless, patients need to be counselled especially about the worse postoperative functional outcome compared to patients with localized PCa.
Collapse
Affiliation(s)
- P Mandel
- Martini-Klinik Prostatakrebszentrum, Universitätsklinikum Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Deutschland.
| | - D Tilki
- Martini-Klinik Prostatakrebszentrum, Universitätsklinikum Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Deutschland
| | - M Graefen
- Martini-Klinik Prostatakrebszentrum, Universitätsklinikum Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Deutschland
| |
Collapse
|
4
|
Kao KR, Popadiuk P, Thoms J, Aoki S, Anwar S, Fitzgerald E, Andrews P, Voisey K, Gai L, Challa S, He Z, Gonzales-Aguirre P, Simmonds A, Popadiuk C. PYGOPUS2 expression in prostatic adenocarcinoma is a potential risk stratification marker for PSA progression following radical prostatectomy. J Clin Pathol 2017; 71:402-411. [PMID: 28924059 DOI: 10.1136/jclinpath-2017-204718] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2017] [Revised: 08/29/2017] [Accepted: 08/29/2017] [Indexed: 12/19/2022]
Abstract
AIMS Prostate cancer (PrCa) is the most frequently diagnosed non-cutaneous cancer in men. Without clear pathological indicators of disease trajectory at diagnosis, management of PrCa is challenging, given its wide-ranging manifestation from indolent to highly aggressive disease. This study examines the role in PrCa of the Pygopus (PYGO)2 chromatin effector protein as a risk stratification marker in PrCa. METHODS RNA expression was performed in PrCa cell lines using Northern and RT-PCR analyses. Protein levels were assessed using immunoblot and immunofluorescence. Immunohistochemistry was performed on tissue microarrays constructed from radical prostatectomies with 5-year patient follow-up data including Gleason score tumour staging, margin and lymph node involvement and prostate serum antigen (PSA) levels. Biochemical recurrence (BR) was defined as a postoperative PSA level of >0.2 nL. Univariate and multivariate analyses were performed using SAS and Kaplan-Meier curves using graphPad (Prism). RESULTS In vitro depletion of PYGO2 by RNAi in both androgen receptor positive and negative PrCa cell lines attenuated growth and reduced Ki67 and 47S rRNA expression, while PYGO2 protein was localised to the nuclei of tumours as determined by immunohistochemistry. High expression levels of PYGO2 in tumours (n=156) were correlated with BR identified as PSA progression, after 7-year follow-up independent of other traditional risk factors. Most importantly, high PYGO2 levels in intermediate grade tumours suggested increased risk of recurrence over those with negative or weak expression. CONCLUSION Our data suggest that elevated PYGO2 expression in primary prostate adenocarcinoma is a potential risk factor for BR.
Collapse
Affiliation(s)
- Kenneth R Kao
- Division of Anatomical Pathology, Laboratory Medicine Program, Eastern Health, St. John's, Canada.,Biomedical Sciences, Memorial University, St. John's, NL, Canada
| | - Paul Popadiuk
- Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada
| | - John Thoms
- Discipline of Oncology, Faculty of Medicine, Memorial University of Newfoundland, St. John's, Canada
| | - Satoko Aoki
- Discipline of Oncology, Faculty of Medicine, Memorial University of Newfoundland, St. John's, Canada
| | - Shahgul Anwar
- Division of Anatomical Pathology, Laboratory Medicine Program, Eastern Health, St. John's, Canada
| | - Emily Fitzgerald
- Biomedical Sciences, Memorial University, St. John's, NL, Canada
| | - Phillip Andrews
- Biomedical Sciences, Memorial University, St. John's, NL, Canada
| | - Kim Voisey
- Division of Anatomical Pathology, Laboratory Medicine Program, Eastern Health, St. John's, Canada
| | - Luis Gai
- Division of Anatomical Pathology, Laboratory Medicine Program, Eastern Health, St. John's, Canada
| | - Satya Challa
- Discipline of Oncology, Faculty of Medicine, Memorial University of Newfoundland, St. John's, Canada
| | - Zhijian He
- Biomedical Sciences, Memorial University, St. John's, NL, Canada
| | | | - Andrea Simmonds
- Division of Anatomical Pathology, Laboratory Medicine Program, Eastern Health, St. John's, Canada
| | - Catherine Popadiuk
- Division of Gynecologic Oncology, Faculty of Medicine, Memorial University of Newfoundland, St. John's, Canada
| |
Collapse
|
5
|
Tang V, Murphy DG, Moon D. Management of Locally Advanced (Nonmetastatic) Prostate Cancer. Prostate Cancer 2016. [DOI: 10.1016/b978-0-12-800077-9.00051-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
6
|
Pretreatment Tables Predicting Pathologic Stage of Locally Advanced Prostate Cancer. Eur Urol 2015; 67:319-25. [DOI: 10.1016/j.eururo.2014.03.013] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2012] [Accepted: 03/12/2014] [Indexed: 11/21/2022]
|
7
|
Stratification of High-risk Prostate Cancer into Prognostic Categories: A European Multi-institutional Study. Eur Urol 2015; 67:157-164. [DOI: 10.1016/j.eururo.2014.01.020] [Citation(s) in RCA: 155] [Impact Index Per Article: 17.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2012] [Accepted: 01/16/2014] [Indexed: 01/23/2023]
|
8
|
Richard V, Paillard MJ, Mouillet G, Lescut N, Maurina T, Guichard G, Montcuquet P, Martin L, Kleinclauss F, Thiery-Vuillemin A. [Neoadjuvant before surgery treatments: state of the art in prostate cancer]. Prog Urol 2014; 24:595-607. [PMID: 24975795 DOI: 10.1016/j.purol.2014.02.005] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2013] [Revised: 11/28/2013] [Accepted: 02/18/2014] [Indexed: 11/25/2022]
Abstract
GOAL To study the impact of systemic treatment in neoadjuvant strategy before surgery in prostate cancer. MATERIALS Literature reviews with data analysis from PubMed search using the keywords "neoadjuvant", "chemotherapy", "hormonal therapy", "prostate surgery", "radical prostatectomy", but also reports from ASCO and ESMO conferences. The articles on neoadjuvant treatment before radiotherapy were excluded. RESULTS First studies with former therapy are more than 15-years-old and with questionable methodology: lack of power to have a clear idea of the impact on survival criteria such as overall survival or relapse-free survival. However, the impact of neoadjuvant hormone therapy on the classic risk factors for relapse (positive margins, intraprostatic disease, positive lymph nodes) was demonstrated by these studies and a Cochrane meta-analysis. The association with hormone therapy seems mandatory in comparison to treatment based solely on chemotherapy and/or targeted therapy. Promising data on the use of new drugs and their combinations arise: abiraterone acetate combined with LHRH analogue showed a fast PSA decrease and higher rates of pathologic complete response. Other results are promising with hormonal blockages at various key points. CONCLUSION Studies with 2nd generation anti-androgene agents or enzyme inhibitors seem to show very promising results. To provide answers about the effectiveness of current neoadjuvant strategy in terms of survival, other studies are needed: randomized phase III or phase II exploring predictive biomarkers. The design of such trials requires a multidisciplinary approach with urologists, oncologists, radiologists and methodologists.
Collapse
Affiliation(s)
- V Richard
- Service d'urologie, CHU de Besançon, 25030 Besançon cedex, France
| | - M-J Paillard
- Service d'oncologie médicale, CHU de Besançon, boulevard Flemming, 25030 Besançon cedex, France
| | - G Mouillet
- Service d'oncologie médicale, CHU de Besançon, boulevard Flemming, 25030 Besançon cedex, France
| | - N Lescut
- Service de radiothérapie, CHU de Besançon, 25030 Besançon cedex, France; UMR1098, SFR IBCT, université de Franche-Comté, 25020 Besançon, France
| | - T Maurina
- Service d'oncologie médicale, CHU de Besançon, boulevard Flemming, 25030 Besançon cedex, France
| | - G Guichard
- Service d'urologie, CHU de Besançon, 25030 Besançon cedex, France
| | - P Montcuquet
- Service d'oncologie médicale, CHU de Besançon, boulevard Flemming, 25030 Besançon cedex, France
| | - L Martin
- Service d'urologie, CHU de Besançon, 25030 Besançon cedex, France
| | - F Kleinclauss
- Service d'urologie, CHU de Besançon, 25030 Besançon cedex, France; Inserm, UMR1098, 25020 Besançon cedex, France; UMR1098, SFR IBCT, université de Franche-Comté, 25020 Besançon, France
| | - A Thiery-Vuillemin
- Service d'oncologie médicale, CHU de Besançon, boulevard Flemming, 25030 Besançon cedex, France; Inserm, UMR1098, 25020 Besançon cedex, France; UMR1098, SFR IBCT, université de Franche-Comté, 25020 Besançon, France.
| |
Collapse
|
9
|
Abstract
PURPOSE OF REVIEW Surgery for high-risk prostate cancer (PCa) is applied frequently nowadays. Nevertheless, this approach is still surrounded by many controversies. The present review discusses the most recent literature regarding surgery for high-risk PCa. RECENT FINDINGS As there is no standard definition of high-risk PCa, outcome comparison between series and treatment approaches is hampered. Nevertheless, recent radical prostatectomy series have shown excellent cancer-specific survival in patients with high-risk PCa. Even for very-high-risk PCa (cT3b-T4 or any cT, N1), surgery may be applied to highly selected patients as a first step of a multimodality approach. Recent experience with robot-assisted surgery opens new possibilities for a minimally invasive approach in this field.Patient selection for surgery was also addressed in recent studies. Excellent cancer-specific survival is seen when specimen-confined PCa is found at final histopathology; a recently published nomogram enables the prediction of specimen-confined disease. Another issue in high-risk PCa is the impact of age and comorbidities on cancer-specific and overall mortality. In a recent study, it was shown that patients with low comorbidity scores, even when at least 70 years old, had a significant risk of dying from their cancer and may benefit most from a surgical approach. A modified extended pelvic lymphadenectomy template was presented, providing optimal removal of positive lymph nodes. SUMMARY Radical prostatectomy with extended pelvic lymphadenectomy delivers very good cancer-related outcomes in high-risk and very-high-risk PCa, often within a multimodal approach. Minimally invasive surgery and improved patient selection will be key to further improve oncological and functional outcomes.
Collapse
|
10
|
You D, Jeong IG, Song C, Cho YM, Hong JH, Kim CS, Ahn H. High percent tumor volume predicts biochemical recurrence after radical prostatectomy in pathological stage T3a prostate cancer with a negative surgical margin. Int J Urol 2013; 21:484-9. [PMID: 24256352 DOI: 10.1111/iju.12348] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2013] [Accepted: 10/21/2013] [Indexed: 11/29/2022]
Abstract
OBJECTIVES To evaluate the impact of percent tumor volume and surgical margin status on biochemical recurrence in pT3-T4 prostate cancer. METHODS A total of 397 patients who had pT3-T4N0 diseases and did not receive neoadjuvant or adjuvant therapy were included for analysis. RESULTS In the entire cohort, prostate-specific antigen (per 1 ng/mL increase; hazard ratio 1.019; P = 0.002), pathological stage (T3b-T4 vs T3a; hazard ratio 2.283; P < 0.001), Gleason score (≥8 vs ≤6; hazard ratio 5.290; P = 0.005), surgical margin status (multiple positive vs negative; hazard ratio 1.839; P = 0.003) and lymphovascular invasion (present vs absent; hazard ratio 1.641; P = 0.008) were independent predictors of recurrence. Percent tumor volume was an independent predictor of recurrence in T3a diseases with negative surgical margins. In analysis using receiver operating characteristic curve, a threshold of 12% showed the best balance of sensitivity and specificity, 66% and 67%, respectively. The 5-year recurrence-free survival rates of pT3a diseases with negative surgical margin were 85.2% for percent tumor volume ≤12% and 57.7% for percent tumor volume >12% (P < 0.001). Patients with pT3a with negative surgical margins and percent tumor volume >12% showed comparable 5-year recurrence-free survival rate compared with those with pT3a with positive surgical margin (57.7% vs 57.6%; P = 0.763). CONCLUSIONS Despite having less impact on recurrence than other clinicopathological variables in pT3-T4 prostate cancer, percent tumor volume can further improve recurrence risk stratification in pT3a diseases with negative surgical margins.
Collapse
Affiliation(s)
- Dalsan You
- Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
| | | | | | | | | | | | | |
Collapse
|
11
|
Perioperative complications of radical retropubic prostatectomy in patients with locally advanced prostate cancer: a comparison with clinically localized prostate cancer. Asian J Androl 2012; 15:241-5. [PMID: 23223030 DOI: 10.1038/aja.2012.120] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Abstract
Radical prostatectomy (RP) continues to be an effective surgical therapy for prostate carcinoma, particularly for organ-confined prostate cancer (PCa). Recently, RP has also been used in the treatment of locally advanced prostate cancer. However, little research has been performed to elucidate the perioperative complications associated with RP in patients with clinically localized or locally advanced PCa. We sought to analyse the incidence of complications in these two groups after radical retropubic prostatectomy (RRP). From June 2002 to July 2010, we reviewed 379 PCa patients who underwent RRP in our hospital. Among these cases, 196 had clinically localized PCa (T1a-T2c: group 1), and 183 had locally advanced PCa (≥T3a: group 2). The overall complication incidence was 21.9%, which was lower than other studies have reported. Perioperative complications in patients with locally advanced PCa mirror those in patients with clinically localized PCa (26.2% vs. 17.8%, P=0.91). Our results showed that perioperative complications could not be regarded as a factor to consider in regarding RP in patients with cT3 or greater.
Collapse
|
12
|
|
13
|
Stone NN, Skouteris VM, Stock RG. Biopsy and implantation of the seminal vesicles. Brachytherapy 2012; 11:334-40. [DOI: 10.1016/j.brachy.2011.12.008] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2009] [Revised: 12/12/2011] [Accepted: 12/14/2011] [Indexed: 10/14/2022]
|
14
|
Trinh QD, Sun M, Sammon J, Menon M, Karakiewicz PI. Reply from Authors re: Joshua J. Meeks, James A. Eastham. Robotic Prostatectomy: The Rise of the Machines or Judgment Day. Eur Urol 2012;61:686–7. Eur Urol 2012. [DOI: 10.1016/j.eururo.2012.01.040] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
15
|
Complications and functional results of surgery for locally advanced prostate cancer. Adv Urol 2012; 2012:706309. [PMID: 22291698 PMCID: PMC3265055 DOI: 10.1155/2012/706309] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2011] [Accepted: 10/06/2011] [Indexed: 02/03/2023] Open
Abstract
The role of surgery in clinical stage T3 prostate cancer (cT3 PCa) is still subject to debate. We reviewed the records of 139 consecutive patients who underwent a radical prostatectomy (RP) for cT3 PCa with a mean follow-up of 8 years. All data related to surgical and perioperative complications were collected. Continence and erectile function were assessed at 12 months postoperatively and long-term oncologic outcomes were analyzed. Rectal injury and injury of the obturator nerve occurred both in 0.7% of cases. No serious in-hospital complications were noted and no reintervention was needed. Lymphatic leakage was noted in 2.2% of patients and 1.4% experienced prolonged drainage of urine. In 7.2%, wound-related problems occurred. Anastomotic stricture occurred in 2.9%. These complication rates were not different compared to surgical series of RP in localized PCa. At 12 months, complete continence was 87.8% and erectile function had fully recovered in 6% and 10% of patients who underwent a non-nerve sparing or unilateral nerve-sparing procedure, respectively. 10-year estimated biochemical PFS, clinical PFS, CSS and OS were 51.8%, 85.6%, 94.6% and 85.9%, respectively. In cT3 PCa, RP is technically feasible with morbidity comparable to RP in clinically localized PCa. Long-term oncologic control was excellent.
Collapse
|
16
|
Barry Delongchamps N, Peyromaure M, Kpatcha F, Beuvon F, Legrand G, Zerbib M. [pT3N0 prostate cancer treated with radical prostatectomy as sole treatment: Oncological results and predictive factors of recurrence]. Prog Urol 2011; 22:100-5. [PMID: 22284594 DOI: 10.1016/j.purol.2011.08.041] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2011] [Revised: 08/29/2011] [Accepted: 08/30/2011] [Indexed: 11/17/2022]
Abstract
OBJECTIVES To evaluate biological free survival in patients with locally advanced prostate cancer treated with radical prostatectomy (RP) as sole treatment, and to analyse predictive factors of recurrence. PATIENTS AND METHOD We retrospectively studied patients treated between 1996 and 2006 for a pT3N0 prostate cancer with RP without any adjuvant treatment. The main endpoint was PSA relapse, defined as two successive elevations of PSA>0.2 ng/mL. An association between PSA free survival and PSA, Gleason score, pathological stage and surgical margins status was statistically assessed. RESULTS A total of 147 patients were included. Median preoperative PSA was of 10 ng/mL. Pathological stage was pT3b in 30% of the cases and surgical margins showed cancer involvement in 63% of the cases. Gleason score was ≥3+4 in 74% of the cases. Postoperative PSA was undetectable in 121 (82%) patients. Median follow up following RP was of 5 years. The 5-year-PSA free survival was of 48%. Multivariate analysis showed that preoperative and postoperative PSA, as well as Gleason score were predictors of PSA relapse (P<0.05). In patients with undetectable postoperative PSA, 5-year-PSA free survival was of 56%. Seminal vesicle involvement and Gleason score ≥3+4 were the only independent predictors of PSA relapse. CONCLUSIONS After RP for pT3N0 prostate cancer, the only predictive factors of recurrence were postoperative PSA and Gleason score. In case of undetectable postoperative PSA, surveillance seems acceptable if Gleason score is <3+4 and in the absence of seminal vesicle involvement.
Collapse
Affiliation(s)
- N Barry Delongchamps
- Department of urology, Cochin hospital, Paris Descartes University, 27, rue du Faubourg-Saint-Jacques, 75014 Paris, France.
| | | | | | | | | | | |
Collapse
|
17
|
Abstract
INTRODUCTION A locally advanced prostate cancer is defined as a malignant process spreading beyond the prostate capsule or in seminal vesicles but without distant metastasis or regional lymph nodes invasion. CLINICAL CLASSIFICATION, PREDICTION AND TREATMENT OF PROSTATE CANCER An exact staging of clinical T3 stadium is usually difficult because of the frequent over and under staging. The risk prognostic stratification is performed through nomograms and ANN (artificial neural networks). The options for treatment are: radical prostatectomy, external radiotherapy and interstitial implantation of radioisotopes, hormonal therapy by androgen blockade. Radical prostatectomy is considered in patients with T3 stage but extensive dissection of lymph nodes, dissection of neurovascular bundle (on tumor side), total removal of seminal vesicle and sometimes resection of bladder neck are obligatory. Postoperative radiotherapy is performed in patients with invasion of seminal vesicles and capsular penetration or with prostate specific antigen value over 0.1 ng/ml, one month after the surgical treatment. Definitive radiotherapy could be used as the best treatment option considering clinical stage, Gleason score, age, starting prostate specific antigen (PSA) value, concomitant diseases, life expectancy, quality of life, through multidisciplinary approach (combined with androgen deprivation). Hormonal therapy in intended for patients who are not eligible for surgical treatment or radiotherapy. Conclusion Management of locally advanced prostate cancer is still controversial and studies fbr better diagnosis and new treatment modalities are ongoing.
Collapse
|
18
|
|
19
|
Soulié M, Rozet F, Hennequin C, Salomon L. Place de la chirurgie dans les tumeurs de la prostate à haut risque. Cancer Radiother 2010; 14:493-9. [DOI: 10.1016/j.canrad.2010.06.006] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2010] [Accepted: 06/02/2010] [Indexed: 10/19/2022]
|
20
|
Walz J, Joniau S, Chun FK, Isbarn H, Jeldres C, Yossepowitch O, Chao-Yu H, Klein EA, Scardino PT, Reuther A, Poppel HV, Graefen M, Huland H, Karakiewicz PI. Pathological results and rates of treatment failure in high-risk prostate cancer patients after radical prostatectomy. BJU Int 2010; 107:765-770. [PMID: 20875089 DOI: 10.1111/j.1464-410x.2010.09594.x] [Citation(s) in RCA: 111] [Impact Index Per Article: 7.9] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Affiliation(s)
- Jochen Walz
- Cancer Prognostics and Health Outcomes Unit, University of Montreal, Montreal, CanadaDepartment of Urology, Institut Paoli-Calmettes, Marseille, FranceDepartment of Urology, University Hospital Katholieke Universiteit, Leuven, BelgiumDepartment of UrologyMartini Clinic, Prostate Cancer Centre, University Medical Centre Eppendorf, Hamburg, GermanySidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, New York, NYGlickman Urologic and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA
| | - Steven Joniau
- Cancer Prognostics and Health Outcomes Unit, University of Montreal, Montreal, CanadaDepartment of Urology, Institut Paoli-Calmettes, Marseille, FranceDepartment of Urology, University Hospital Katholieke Universiteit, Leuven, BelgiumDepartment of UrologyMartini Clinic, Prostate Cancer Centre, University Medical Centre Eppendorf, Hamburg, GermanySidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, New York, NYGlickman Urologic and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA
| | - Felix K Chun
- Cancer Prognostics and Health Outcomes Unit, University of Montreal, Montreal, CanadaDepartment of Urology, Institut Paoli-Calmettes, Marseille, FranceDepartment of Urology, University Hospital Katholieke Universiteit, Leuven, BelgiumDepartment of UrologyMartini Clinic, Prostate Cancer Centre, University Medical Centre Eppendorf, Hamburg, GermanySidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, New York, NYGlickman Urologic and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA
| | - Hendrik Isbarn
- Cancer Prognostics and Health Outcomes Unit, University of Montreal, Montreal, CanadaDepartment of Urology, Institut Paoli-Calmettes, Marseille, FranceDepartment of Urology, University Hospital Katholieke Universiteit, Leuven, BelgiumDepartment of UrologyMartini Clinic, Prostate Cancer Centre, University Medical Centre Eppendorf, Hamburg, GermanySidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, New York, NYGlickman Urologic and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA
| | - Claudio Jeldres
- Cancer Prognostics and Health Outcomes Unit, University of Montreal, Montreal, CanadaDepartment of Urology, Institut Paoli-Calmettes, Marseille, FranceDepartment of Urology, University Hospital Katholieke Universiteit, Leuven, BelgiumDepartment of UrologyMartini Clinic, Prostate Cancer Centre, University Medical Centre Eppendorf, Hamburg, GermanySidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, New York, NYGlickman Urologic and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA
| | - Ofer Yossepowitch
- Cancer Prognostics and Health Outcomes Unit, University of Montreal, Montreal, CanadaDepartment of Urology, Institut Paoli-Calmettes, Marseille, FranceDepartment of Urology, University Hospital Katholieke Universiteit, Leuven, BelgiumDepartment of UrologyMartini Clinic, Prostate Cancer Centre, University Medical Centre Eppendorf, Hamburg, GermanySidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, New York, NYGlickman Urologic and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA
| | - Hsu Chao-Yu
- Cancer Prognostics and Health Outcomes Unit, University of Montreal, Montreal, CanadaDepartment of Urology, Institut Paoli-Calmettes, Marseille, FranceDepartment of Urology, University Hospital Katholieke Universiteit, Leuven, BelgiumDepartment of UrologyMartini Clinic, Prostate Cancer Centre, University Medical Centre Eppendorf, Hamburg, GermanySidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, New York, NYGlickman Urologic and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA
| | - Eric A Klein
- Cancer Prognostics and Health Outcomes Unit, University of Montreal, Montreal, CanadaDepartment of Urology, Institut Paoli-Calmettes, Marseille, FranceDepartment of Urology, University Hospital Katholieke Universiteit, Leuven, BelgiumDepartment of UrologyMartini Clinic, Prostate Cancer Centre, University Medical Centre Eppendorf, Hamburg, GermanySidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, New York, NYGlickman Urologic and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA
| | - Peter T Scardino
- Cancer Prognostics and Health Outcomes Unit, University of Montreal, Montreal, CanadaDepartment of Urology, Institut Paoli-Calmettes, Marseille, FranceDepartment of Urology, University Hospital Katholieke Universiteit, Leuven, BelgiumDepartment of UrologyMartini Clinic, Prostate Cancer Centre, University Medical Centre Eppendorf, Hamburg, GermanySidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, New York, NYGlickman Urologic and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA
| | - Alwyn Reuther
- Cancer Prognostics and Health Outcomes Unit, University of Montreal, Montreal, CanadaDepartment of Urology, Institut Paoli-Calmettes, Marseille, FranceDepartment of Urology, University Hospital Katholieke Universiteit, Leuven, BelgiumDepartment of UrologyMartini Clinic, Prostate Cancer Centre, University Medical Centre Eppendorf, Hamburg, GermanySidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, New York, NYGlickman Urologic and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA
| | - Hein Van Poppel
- Cancer Prognostics and Health Outcomes Unit, University of Montreal, Montreal, CanadaDepartment of Urology, Institut Paoli-Calmettes, Marseille, FranceDepartment of Urology, University Hospital Katholieke Universiteit, Leuven, BelgiumDepartment of UrologyMartini Clinic, Prostate Cancer Centre, University Medical Centre Eppendorf, Hamburg, GermanySidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, New York, NYGlickman Urologic and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA
| | - Markus Graefen
- Cancer Prognostics and Health Outcomes Unit, University of Montreal, Montreal, CanadaDepartment of Urology, Institut Paoli-Calmettes, Marseille, FranceDepartment of Urology, University Hospital Katholieke Universiteit, Leuven, BelgiumDepartment of UrologyMartini Clinic, Prostate Cancer Centre, University Medical Centre Eppendorf, Hamburg, GermanySidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, New York, NYGlickman Urologic and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA
| | - Hartwig Huland
- Cancer Prognostics and Health Outcomes Unit, University of Montreal, Montreal, CanadaDepartment of Urology, Institut Paoli-Calmettes, Marseille, FranceDepartment of Urology, University Hospital Katholieke Universiteit, Leuven, BelgiumDepartment of UrologyMartini Clinic, Prostate Cancer Centre, University Medical Centre Eppendorf, Hamburg, GermanySidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, New York, NYGlickman Urologic and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA
| | - Pierre I Karakiewicz
- Cancer Prognostics and Health Outcomes Unit, University of Montreal, Montreal, CanadaDepartment of Urology, Institut Paoli-Calmettes, Marseille, FranceDepartment of Urology, University Hospital Katholieke Universiteit, Leuven, BelgiumDepartment of UrologyMartini Clinic, Prostate Cancer Centre, University Medical Centre Eppendorf, Hamburg, GermanySidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, New York, NYGlickman Urologic and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA
| |
Collapse
|
21
|
Ishidoya S. Editorial comment to Feasibility of antegrade radical prostatectomy for clinically locally advanced prostate cancer: a comparative study with clinically localized disease. Int J Urol 2010; 17:725-6. [PMID: 20649829 DOI: 10.1111/j.1442-2042.2010.02577.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
22
|
Casey JT, Meeks JJ, Greco KA, Wu SD, Nadler RB. Outcomes of Locally Advanced (T3 or Greater) Prostate Cancer in Men Undergoing Robot-Assisted Laparoscopic Prostatectomy. J Endourol 2009; 23:1519-22. [DOI: 10.1089/end.2009.0388] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- Jessica T. Casey
- Department of Urology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois
| | - Joshua J. Meeks
- Department of Urology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois
| | - Kristin A. Greco
- Department of Urology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois
| | - Simon D. Wu
- Department of Urology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois
| | - Robert B. Nadler
- Department of Urology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois
| |
Collapse
|
23
|
Krengli M, Terrone C, Ballarè A, Loi G, Tarabuzzi R, Marchioro G, Beldì D, Mones E, Bolchini C, Volpe A, Frea B. Intraoperative radiotherapy during radical prostatectomy for locally advanced prostate cancer: technical and dosimetric aspects. Int J Radiat Oncol Biol Phys 2009; 76:1073-7. [PMID: 19625135 DOI: 10.1016/j.ijrobp.2009.03.037] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2009] [Revised: 02/26/2009] [Accepted: 03/05/2009] [Indexed: 11/26/2022]
Abstract
PURPOSE To analyze the feasibility of intraoperative radiotherapy (IORT) in patients with high-risk prostate cancer and candidates for radical prostatectomy. METHODS AND MATERIALS A total of 38 patients with locally advanced prostate cancer were enrolled. No patients had evidence of lymph node or distant metastases, probability of organ-confined disease >25%, or risk of lymph node involvement >15% according to the Memorial Sloan-Kettering Cancer Center Nomogram. The IORT was delivered after exposure of the prostate by a dedicated linear accelerator with beveled collimators using electrons of 9 to 12 MeV to a total dose of 10-12 Gy. Rectal dose was measured in vivo by radiochromic films placed on a rectal probe. Adminstration of IORT was followed by completion of radical prostatectomy and regional lymph node dissection. All cases with extracapsular extension and/or positive margins were scheduled for postoperative radiotherapy. Patients with pT3 to pT4 disease or positive nodes received adjuvant hormonal therapy. RESULTS Mean dose detected by radiochromic films was 3.9 Gy (range, 0.4-8.9 Gy) to the anterior rectal wall. The IORT procedure lasted 31 min on average (range, 15-45 min). No major intra- or postoperative complications occurred. Minor complications were observed in 10/33 (30%) of cases. Of the 27/31 patients who completed the postoperative external beam radiotherapy, 3/27 experienced Grade 2 rectal toxicity and 1/27 experienced Grade 2 urinary toxicity. CONCLUSIONS Use of IORT during radical prostatectomy is feasible and allows safe delivery of postoperative external beam radiotherapy to the tumor bed without relevant acute rectal toxicity.
Collapse
Affiliation(s)
- Marco Krengli
- Department of Radiotherapy, University Hospital Maggiore della Carità, Novara, Italy.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Foley CL, Feneley MR. The clinical significance and therapeutic implications of extraprostatic invasion. Surg Oncol 2009; 18:203-12. [PMID: 19398328 DOI: 10.1016/j.suronc.2009.03.004] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
Invasion of the prostatic margin by cancer establishes a higher risk of disease progression and treatment failure depending upon its extent and other clinical factors. Pathological stage is the most important single prognostic indicator, but determined reliably only in patients having radical prostatectomy. Tumour beyond the prostatic margin or its invasion into the seminal vesicle defines the local stage category as T3, and when confirmed by pathological examination the extent of prostatic margin involvement has prognostic significance. Prediction of extraprostatic invasion may influence therapeutic decisions, but can be difficult to determine for the individual patient prior to treatment. In some individuals having radical prostatectomy, the finding of extraprostatic invasion is unsuspected, and fortunately for the majority of these men the treatment remains curative. On the other hand, when extraprostatic invasion is suspected prior to or at surgery, wide excision may be necessary to achieve negative surgical margins, with other factors contributing independently to the likelihood of subsequent progression. Radiotherapy is an effective alternative treatment for clinical stage T3 and high-risk clinically localized cancer. Recent technological advances and use of combination modality treatment with radiation and hormone manipulation have improved survival outcomes and reduced side-effects. Radiation also has its place as adjuvant treatment following radical prostatectomy in high-risk disease, or as salvage following PSA recurrence, with ongoing trials evaluating potential benefit and toxicity. For clinically localised stage T3 prostate cancer, treatment with surgery or radiotherapy may be highly effective, but multimodality interventions are increasingly being used for primary treatment where clinical assessment indicates that there would otherwise be a high risk for disease progression and therapeutic failure.
Collapse
|
25
|
Abstract
Recent retrospective monocentric studies have demonstrated favorable 15-year cancer-specific survival (CSS) rates of up to 86% using radical prostatectomy as part of multimodal treatment in locally advanced prostate cancer (T3-4, N0, M0). Patients most likely to benefit from surgery include those with a biopsy Gleason score < or =8, a prostate-specific antigen level <20 ng/ml, and cT3a cancer. Patients must be informed that additional treatment after prostatectomy might be necessary (30-70%; radiotherapy, hormonal therapy). Urinary incontinence may occur in up to 20%, and severe incontinence (more than two pads per day) is observed in up to 6%.Adjuvant radiotherapy should be considered individually and is not routinely recommended. Extended pelvic lymphadenectomy should be performed, although it has only a minor impact on survival. However, even in patients with lymph node micrometastasis, 10-year CSS can be achieved in 85.6% with the use of additional hormonal therapy. Cancer progression can possibly be delayed by surgical excision of the primary tumor, even in patients with metastasis. The existing data must be checked in prospective randomized trials.
Collapse
Affiliation(s)
- R-J Palisaar
- Urologische Klinik,Marienhospital Herne, Klinikum der Ruhr-Universität Bochum, Widumer Strasse 8, 44627, Herne, Deutschland.
| | | |
Collapse
|
26
|
Soulié M, Thoulouzan M, Péneau M, Richaud P, Ravery V. La chirurgie du cancer de la prostate au stade localement avancé. Revue du comité de cancérologie de l’AFU (sous-comité « Prostate »). Prog Urol 2008; 18:1031-7. [DOI: 10.1016/j.purol.2008.09.051] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2008] [Revised: 06/11/2008] [Accepted: 09/19/2008] [Indexed: 11/24/2022]
|
27
|
Kelly WK, Halabi S, Elfiky A, Ou SS, Bogart J, Zelefsky M, Small E. Multicenter phase 2 study of neoadjuvant paclitaxel, estramustine phosphate, and carboplatin plus androgen deprivation before radiation therapy in patients with unfavorable-risk localized prostate cancer. Cancer 2008; 113:3137-45. [DOI: 10.1002/cncr.23910] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
28
|
White WM, Sadetsky N, Waters WB, Carroll PR, Litwin MS. Quality of life in men with locally advanced adenocarcinoma of the prostate: an exploratory analysis using data from the CaPSURE database. J Urol 2008; 180:2409-13; discussion 2414. [PMID: 18930270 DOI: 10.1016/j.juro.2008.08.079] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2008] [Indexed: 11/19/2022]
Abstract
PURPOSE We present longitudinal quality of life outcomes in a national observational cohort of men with locally advanced prostate adenocarcinoma. MATERIALS AND METHODS The CaPSURE registry was used to evaluate quality of life in men with clinical T3 or T4 prostate adenocarcinoma who underwent primary treatment and had a minimum followup of 2 years. Records were reviewed for treatment, patient age, T stage, prostate specific antigen at diagnosis, body mass index, and initial and posttreatment quality of life using the SF-36 and UCLA-PCI questionnaires, which can each be scored from 0 to 100 with higher scores indicating better outcomes. The association of treatment type and quality of life changes after treatment were evaluated with multivariate mixed model analysis, adjusting for age, time of quality of life assessment, and interaction between treatment and time. RESULTS Of the 13,740 men enrolled in CaPSURE 608 (4.42%) presented with T3 or T4 tumors. In this subgroup 151 men completed baseline and a minimum of 2 years of followup with quality of life data available. These men underwent primary treatment with radical prostatectomy (21%), cryotherapy (8%), brachytherapy (17%) or hormonal ablation (54%). The treatment cohort demonstrated significant decreases in quality of life, most profoundly in urinary and sexual function. Mean urinary function was 91 at baseline, which decreased to 82, 83 and 82 at 1, 2 and 3 years after treatment, respectively (p = 0.04). Mean sexual function was 38 at baseline, which decreased to 15, 16 and 14 at 1, 2 and 3 years after treatment, respectively (p <0.01). On multivariate analysis quality of life varied significantly by treatment type (p <0.01). CONCLUSIONS Treatment for locally advanced prostate adenocarcinoma is associated with a significant burden in patients, notably decrements in urinary and sexual function. Clinicians should consider the impact that treatment imparts on quality of life when counseling patients with locally advanced disease.
Collapse
Affiliation(s)
- Wesley M White
- Department of Urology, University of Tennessee Medical Center, Knoxville, Tennessee 37920, USA.
| | | | | | | | | |
Collapse
|
29
|
Stock RG. Counterpoint: High-risk prostate cancer: The case for combination brachytherapy and external beam irradiation. Brachytherapy 2008; 7:280-2; discussion 283. [DOI: 10.1016/j.brachy.2008.08.005] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
30
|
|
31
|
Burkhard FC, Studer UE. The role of lymphadenectomy in high risk prostate cancer. World J Urol 2008; 26:231-6. [DOI: 10.1007/s00345-008-0251-6] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2008] [Accepted: 02/26/2008] [Indexed: 10/22/2022] Open
|
32
|
Francini G, Paolelli L, Francini E, Pascucci A, Manganelli A, Salvestrini F, Petrioli R. Effect of neoadjuvant epirubicin and total androgen blockade on complete pathological response in patients with clinical stage T3/T4 prostate cancer. Eur J Surg Oncol 2008; 34:216-21. [PMID: 17502132 DOI: 10.1016/j.ejso.2007.03.016] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2007] [Accepted: 03/20/2007] [Indexed: 11/15/2022] Open
Abstract
AIMS Most patients with stage T3-T4 prostate cancer experience disease relapse despite radiation and/or hormonal therapy, and their management remains controversial. We investigated the feasibility of, and the pathological response induced by neoadjuvant chemo-hormonal treatment in men with clinical stage T3/T4. METHODS Fifteen patients underwent neoadjuvant therapy consisting of weekly intravenous infusions of epirubicin 30mg/m(2) and total androgen blockade (TAB) for three months before undergoing radical prostatectomy, after which all received locoregional conformal radiotherapy (66Gy) and then continued with TAB and three additional months of epirubicin. RESULTS After neoadjuvant therapy, PSA levels decreased in all 15 patients and became undetectable in two. None of the patients achieved a complete pathological response, but a 35-75% reduction in tumour size was observed in all cases, and all the patients were able to undergo successful prostatectomy. Pathological assessments of the surgical specimens revealed negative margins in 13 patients. After a median follow-up of 34 months (range 11-62), 14 patients (93%) are still clinically and biochemically disease free. No grade 3 or 4 complications occurred. CONCLUSION This study suggests that neoadjuvant treatment with epirubicin and TAB is feasible and well tolerated in patients with clinical stage T3-T4 prostate cancer.
Collapse
Affiliation(s)
- G Francini
- Department of Human Pathology and Oncology, Medical Oncology Section, University of Siena, Policlinico Le Scotte, Viale Bracci 11, 53100 Siena, Italy.
| | | | | | | | | | | | | |
Collapse
|
33
|
Van Poppel H, Joniau S, Haustermans K. Surgery alone for advanced prostate cancer? EJC Suppl 2007. [DOI: 10.1016/s1359-6349(07)70036-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
|
34
|
Esquena Fernández S, Maroto Rey P, Sancho Pardo G, Palou Redorta J, Villavicencio Mavrich H. [Current treatment in high risk and locally advanced prostate cancer]. Actas Urol Esp 2007; 31:445-51. [PMID: 17711162 DOI: 10.1016/s0210-4806(07)73667-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Treatment of locally advanced prostate cancer remains controversial. Treatment options include radical prostatectomy (PR), radiotherapy (RT) and hormonotherapy (HT). A Medline database search with key words "prostate cancer", "locally advanced", "high risk" and "treatment" in articles published during the last 15 years was done. Fifty one out of 329 papers were selected and reviewed. Selection criteria were a minimum of scientific evidence level of IIa, except for some specific level IV reference. Numerous randomized studies show that patients may benefit of a combined therapy with RT and HT. RP has shown its usefulness in selected cases of locally advanced prostate cancer. Results of long follow-up series are similar to those obtained with RT and HT. Furthermore, the possibility of clinical over staging is an argument in favour of RP. We perform an updated revision of every possible choice available in the treatment of these tumours.
Collapse
|
35
|
Dotan ZA, Ramon J. Staging of prostate cancer. RECENT RESULTS IN CANCER RESEARCH. FORTSCHRITTE DER KREBSFORSCHUNG. PROGRES DANS LES RECHERCHES SUR LE CANCER 2007; 175:109-30. [PMID: 17432557 DOI: 10.1007/978-3-540-40901-4_8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/14/2023]
Affiliation(s)
- Zohar A Dotan
- The Chaim Sheba Medical Center, Tel-Hashomer, Ramat-Gan, Israel
| | | |
Collapse
|
36
|
Gontero P, Marchioro G, Pisani R, Zaramella S, Sogni F, Kocjancic E, Mondaini N, Bonvini D, Tizzani A, Frea B. Is Radical Prostatectomy Feasible in All Cases of Locally Advanced Non-Bone Metastatic Prostate Cancer? Results of a Single-Institution Study. Eur Urol 2007; 51:922-9; discussion 929-30. [PMID: 17049718 DOI: 10.1016/j.eururo.2006.08.050] [Citation(s) in RCA: 60] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2006] [Accepted: 08/25/2006] [Indexed: 11/27/2022]
Abstract
OBJECTIVES Previous prospective studies of the surgical treatment of locally advanced prostate cancer have enrolled patients selected on the basis of a limited T3 disease extension. The aim of the present study was to assess the feasibility and the oncologic outcome of radical prostatectomy administered to a consecutive unselected series of advanced, non-bone metastatic prostate cancers. METHODS Between March 1998 and February 2003 radical prostatectomy was offered at our institution to any patient diagnosed with prostate cancer with no sign of extranodal metastatic disease. Data on morbidity and survival for 51 clinically advanced cases (any T>/=3, N0-N1, or any N1 or M1a disease according to the TNM 2002 classification system) operated on by a single expert surgeon were compared with a series of 152 radical prostatectomies performed during the same period by the same operator for clinically organ-confined disease. Adjuvant treatment was administered according to current guidelines. RESULTS The two groups did not differ significantly in surgical morbidity except for blood transfusion, operative time, and lymphoceles, which showed a higher rate in patients with advanced disease. The Kaplan-Meier estimate of overall survival and prostate cancer-specific survival at 7 yr were 76.69% and 90.2% in the advanced disease group and 88.4% and 99.3% in the organ-confined disease group, respectively. CONCLUSIONS Even in the scenario of extensive surgical indications up to M1a disease, radical prostatectomy proved to be technically feasible and to have an acceptable morbidity rate compared with organ-confined disease. Our initial survival data strengthen the role for surgery as an essential part in the multimodal approach to treating advanced prostate cancer.
Collapse
Affiliation(s)
- Paolo Gontero
- Clinica Urologica I, Università degli Studi di Torino, Torino, Italy.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Wirth MP, Hakenberg OW, Froehner M. Optimal treatment of locally advanced prostate cancer. World J Urol 2007; 25:169-76. [PMID: 17333200 DOI: 10.1007/s00345-007-0158-7] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/27/2006] [Accepted: 02/01/2007] [Indexed: 11/29/2022] Open
Abstract
The treatment of clinically locally advanced prostate cancer (cT3-4) is subject to controversies. Patients with lymph node metastases as well as patients with overstaged localized and thus curable disease fall into this category. Radical prostatectomy, external beam radiotherapy and early or deferred hormonal therapy are possible treatment options. Multimodal treatment (i.e., a combination of these options) is frequently used. After radical prostatectomy, Gleason score-adjusted disease-specific survival does not differ meaningfully between the tumor stages pT2 and pT3-4. In the case of lymph node metastases after radical prostatectomy, but not in node-negative disease, adjuvant hormonal treatment seems to improve survival. Adjuvant radiotherapy may improve biochemical and local control in locally advanced prostate cancer, a survival benefit has, however, not yet been proven. External beam radiotherapy alone provides unfavourable survival rates in locally advanced prostate cancer. Adjuvant hormonal treatment may improve outcome in this setting. When no curative treatment is chosen, early hormonal treatment seems to provide modest benefit compared with deferred therapy.
Collapse
Affiliation(s)
- Manfred P Wirth
- Department of Urology, University Hospital, Carl Gustav Carus, Technical University of Dresden, Fetscherstrasse 74, 01307 Dresden, Germany.
| | | | | |
Collapse
|
38
|
Hakenberg OW, Fröhner M, Wirth MP. Treatment of Locally Advanced Prostate Cancer – The Case for Radical Prostatectomy. Urol Int 2006; 77:193-9. [PMID: 17033204 DOI: 10.1159/000094808] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
The treatment of clinically locally advanced prostate carcinoma (stage cT3) remains controversial. One of the main reasons for this controversy results from the substantial staging error attached to the clinical diagnosis cT3 with overstaged T2 tumors and understaged node-positive cases. Treatment options in this situation include radical prostatectomy, external beam radiotherapy, immediate or delayed androgen deprivation treatment and the so-called 'watchful waiting'. Acceptable and often surprisingly good tumor-specific survival rates have been reported for radical prostatectomy in pT3 series--based on good clinical case selection--approaching those of pT2 series. In lymph node-positive pT3 cases, adjuvant hormone deprivation seems to prolong survival which it does not in lymph node-negative pT3 disease. A benefit of adjuvant external beam radiotherapy after radical prostatectomy for pT3 cases in prolonging overall survival has not been shown, despite the fact that it can prevent or delay biochemical and local recurrence. External beam radiotherapy as the only treatment for cT3 disease results in unfavorable tumor-specific survival rates, which can be significantly improved with adjuvant hormonal treatment with LHRH agonists. If, in case of advanced age and/or significant comorbidity, primary hormonal treatment is chosen, early hormonal deprivation therapy seems to offer marginal benefits in survival compared to delayed treatment.
Collapse
Affiliation(s)
- Oliver W Hakenberg
- Klinik und Poliklinik für Urologie, Universitätsklinikum Carl Gustav Carus der Technischen Universität Dresden, Dresden, Germany.
| | | | | |
Collapse
|
39
|
Stock RG, Ho A, Cesaretti JA, Stone NN. Changing the patterns of failure for high-risk prostate cancer patients by optimizing local control. Int J Radiat Oncol Biol Phys 2006; 66:389-94. [PMID: 16965991 DOI: 10.1016/j.ijrobp.2006.05.072] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2006] [Revised: 05/03/2006] [Accepted: 05/04/2006] [Indexed: 10/24/2022]
Abstract
PURPOSE Standard therapies for high-risk prostate cancer have resulted in suboptimal outcomes with both local and distant failures. Prostate-specific antigen (PSA) and distant metastases rates as well as biopsy outcomes are reported after a regimen of trimodality therapy with hormonal, radioactive seed, and external beam radiation therapy to demonstrate how patterns of failure are changed when local control is optimized. METHODS AND MATERIALS From 1994 to 2003, a total of 360 patients with high-risk prostate cancer were treated with trimodality therapy. Patients were defined as being at high risk if they possessed at least one of the following high-risk features: Gleason score 8 to 10, PSA>20, clinical stage t2c to t3, or two or more intermediate risk features: Gleason score 7, PSA>10 to 20, or stage t2b. Patients were followed for a median of 4.25 years (range, 2 to 10 years). RESULTS The actuarial 7-year freedom from PSA failure and freedom from distant metastases (FFDM) rates were 83% and 89% respectively. Patients (n=51) developing PSA failure exhibited aggressive disease behavior with short PSA doubling times (median, 5 months) and a 7-year freedom from distant metastases rate of 48%. Local control was high. The last posttreatment biopsy results were negative in 97% of cases (68 of 70 patients). In multivariate analysis, only PSA>20 predicted biochemical failure (p=0.04), and only seminal vesicle status predicted developing distant failure (p=0.01). CONCLUSIONS Trimodality therapy results in excellent local control that alters patterns of failure, resulting in similar actuarial biochemical and distant failure rates. Most failures appear to be distant and exhibit biologically aggressive behavior.
Collapse
Affiliation(s)
- Richard G Stock
- Department of Radiation Oncology, Mount Sinai School of Medicine, New York, NY 10029, USA.
| | | | | | | |
Collapse
|
40
|
Carver BS, Bianco FJ, Scardino PT, Eastham JA. Long-term outcome following radical prostatectomy in men with clinical stage T3 prostate cancer. J Urol 2006; 176:564-8. [PMID: 16813890 DOI: 10.1016/j.juro.2006.03.093] [Citation(s) in RCA: 170] [Impact Index Per Article: 9.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/15/2005] [Indexed: 10/24/2022]
Abstract
PURPOSE We evaluated patients at our institution who underwent radical prostatectomy for clinical stage T3 prostate cancer to determine their long-term clinical outcomes. MATERIALS AND METHODS We reviewed our prospective surgical database and identified 176 men who underwent radical retropubic prostatectomy for clinical stage T3 prostate cancer from 1983 to 2003. Clinical and pathological data were reviewed and evaluated in a Cox proportional hazards model to determine preoperative predictors of biochemical recurrence. Clinical progression following biochemical recurrence was evaluated and clinical failure was defined as the development of clinical metastases or progression to hormone refractory prostate cancer. RESULTS Of the 176 patients with cT3 prostate cancer 64 (36%) received neoadjuvant hormonal therapy. At a mean followup of 6.4 years 84 (48%) patients had disease recurrence with a median time to biochemical recurrence of 4.6 years. The actuarial 10-year probability of freedom from recurrence was 44%. On multivariate analysis biopsy Gleason score, pretreatment serum prostate specific antigen and year of surgery were independent predictors of biochemical recurrence. Neoadjuvant hormonal therapy was not a significant predictor of biochemical recurrence. Following biochemical recurrence clinical failure developed in 30 of 84 (36%) men with a median time of 11 years. Overall the 5, 10 and 15-year probabilities of death from prostate cancer were 6%, 15% and 24%, respectively. CONCLUSIONS More than half (52%) of our patients remained free of disease recurrence following radical prostatectomy. In our series neoadjuvant hormonal therapy offered no advantage with respect to disease recurrence. Radical prostatectomy remains an integral component in the treatment of select patients with clinical stage T3 prostate cancer.
Collapse
Affiliation(s)
- Brett S Carver
- Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
| | | | | | | |
Collapse
|
41
|
Miyake H, Sakai I, Inoue TA, Hara I, Fujisawa M. The Limited Significance of a Longer Duration of Neoadjuvant Hormonal Therapy prior to Radical Prostatectomy for High-Risk Prostate Cancer in Japanese Men. Urol Int 2006; 77:122-6. [PMID: 16888415 DOI: 10.1159/000093904] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2005] [Accepted: 02/27/2006] [Indexed: 11/19/2022]
Abstract
INTRODUCTION The objective of this study was to evaluate the therapeutic significance of a longer duration of neoadjuvant hormonal therapy (NHT) followed by radical prostatectomy (RP) in Japanese men with high-risk prostate cancer. MATERIALS AND METHODS This study included a total of 42 patients with high-risk prostate cancer who were treated with NHT for >or=8 months prior to RP. In this series high-risk prostate cancer was defined as clinical stage T2c or T3, pretreatment serum prostate-specific antigen (PSA) >20 ng/ml and/or a biopsy Gleason score of 8-10. Biochemical recurrence was defined as a serum PSA level of >or=0.2 ng/ml. The data of these patients were retrospectively reviewed to clarify the relationships between treatment outcomes and various clinicopathological parameters. RESULTS The clinical stage was T2c in 13 patients and T3 in 29, the median value of pretreatment serum PSA was 43.3 ng/ml (range 9.7-322.2), and the biopsy Gleason score was 6 in 3 patients, 7 in 16 and >or=8 in 23. Following NHT (median 12 months, range 8-27), the median value of serum PSA decreased to 0.05 ng/ml (<0.01-18.3 ng/ml), and 15 patients (35.7%) were pathologically downstaged. During the median follow-up of 38 months (range 8-58), 11 patients (26.2%) developed biochemical recurrence, and the multivariate analysis identified pretreatment serum PSA, biopsy Gleason score and percentage of positive biopsy core as independent predictors of biochemical recurrence. The 3-year biochemical recurrence-free survival rate of the 42 patients was 68.3%, which was not significantly different from that of 34 patients who underwent RP for high-risk prostate cancer without NHT during the same period. CONCLUSION A longer duration of NHT followed by RP for patients with high-risk prostate cancer resulted in a comparatively favorable outcome. However, despite the nonrandomized retrospective analysis, the present findings suggest no significant impact of long-term NHT on biochemical recurrence. Longer follow-up is needed to determine whether this therapeutic strategy is beneficial for high-risk prostate cancer patients.
Collapse
Affiliation(s)
- Hideaki Miyake
- Department of Urology, Hyogo Medical Center for Adults, Akashi, Japan.
| | | | | | | | | |
Collapse
|
42
|
Spiess PE, Leibovici D, Pisters LL. Surgery for locally advanced disease. Curr Urol Rep 2006; 7:209-16. [PMID: 16630524 DOI: 10.1007/s11934-006-0023-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
Locally advanced prostate cancer is diagnosed in approximately one in four new cases of prostate cancer. The estimated disease-specific mortality rate resulting from monotherapy with either surgery or radiotherapy is a disappointing 75%. A multimodality treatment approach could offer more promising results. In addition, several key factors related to surgical treatment of locally advanced prostate cancer may optimize the oncologic results and minimize patient morbidity. In this report, we summarize some of the anatomic features and technical concepts associated with the surgical management of this disease and review recently published results of the outcomes of surgery and neoadjuvant or adjuvant chemohormonal therapy for locally advanced prostate cancer.
Collapse
Affiliation(s)
- Philippe E Spiess
- Department of Urology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1373, Houston, TX 77030, USA
| | | | | |
Collapse
|
43
|
Abstract
The management of clinically locally advanced prostate carcinoma (cT3) remains a controversial issue. The clinical stage cT3 consists of a mixture of overstaged T2 carcinomas but also contains lymph node-positive cases. Treatment options consist of radical prostatectomy, external beam radiotherapy, hormonal deprivation (early or delayed) and the so-called watchful waiting. In many cases multimodal therapy is used. Radical prostatectomy in the clinical stage T3 can achieve acceptable tumour-specific survival rates if patients are well selected. In this way, tumour-specific survival rates can be reached for pT3 patients which closely approach those of pT2 cases. In lymph node-positive cases after radical prostatectomy adjuvant hormonal treatment can prolong survival, but not in lymph node-negative cases. A benefit of adjuvant radiotherapy after radical prostatectomy has not been proven. Although it can postpone or prevent biochemical recurrence, it does not prolong overall survival. Treatment of stage cT3 by external beam radiotherapy alone results in unfavourable tumour-specific survival rates. In these cases definite improvement can be achieved by adjuvant androgen deprivation with LHRH analogues. If in case of severe comorbidity or advanced age primary hormonal treatment is chosen, early vs deferred treatment seems to prolong survival marginally.
Collapse
Affiliation(s)
- M P Wirth
- Klinik und Poliklinik für Urologie, Universitätsklinikum Carl Gustav Carus, Technische Universität, Dresden.
| | | | | |
Collapse
|
44
|
Bracarda S, de Cobelli O, Greco C, Prayer-Galetti T, Valdagni R, Gatta G, de Braud F, Bartsch G. Cancer of the prostate. Crit Rev Oncol Hematol 2005; 56:379-96. [PMID: 16310371 DOI: 10.1016/j.critrevonc.2005.03.010] [Citation(s) in RCA: 75] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2005] [Accepted: 03/16/2005] [Indexed: 11/24/2022] Open
Abstract
Prostate carcinoma, with about 190,000 new cases occurring each year (15% of all cancers in men), is the most frequent cancer among men in northern and western Europe. Causes of the disease are essentially unknown, although hormonal factors are involved, and diet may exert an indirect influence; some genes, potentially involved in hereditary prostate cancer (HPC) have been identified. A suspect of prostate cancer may derive from elevated serum prostate-specific antigen (PSA) values and/or a suspicious digital rectal examination (DRE) finding. For a definitive diagnosis, however, a positive prostate biopsy is requested. Treatment strategy is defined according to initial PSA stage, and grade of the disease and age and general conditions of the patient. In localized disease, watchful waiting is indicated as primary option in patients with well or moderately differentiated tumours and a life expectancy <10 years, while radical prostatectomy and radiotherapy (with or without hormone-therapy) could be appropriate choices in the remaining cases. Hormone-therapy is the treatment of choice, combined with radiotherapy, for locally advanced or bulky disease and is effective, but not curative, in 80-85% of the cases of advanced disease. Patients who develop a hormone-refractory prostate cancer disease (HRPC) have to be evaluated for chemotherapy because of the recent demonstration of improved overall survival (2-2.5 months) and quality of life with docetaxel in more than 1,600 cases.
Collapse
|
45
|
Advanced prostate cancer: place of surgery. EJC Suppl 2005. [DOI: 10.1016/s1359-6349(05)80289-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
|
46
|
Hsu CY, Joniau S, Van Poppel H. Radical Prostatectomy for Locally Advanced Prostate Cancer: Technical Aspects of Radical Prostatectomy. ACTA ACUST UNITED AC 2005. [DOI: 10.1016/j.euus.2005.03.004] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
47
|
Meng MV, Elkin EP, Latini DM, Duchane J, Carroll PR. TREATMENT OF PATIENTS WITH HIGH RISK LOCALIZED PROSTATE CANCER: RESULTS FROM CANCER OF THE PROSTATE STRATEGIC UROLOGICAL RESEARCH ENDEAVOR (CaPSURE). J Urol 2005; 173:1557-61. [PMID: 15821485 DOI: 10.1097/01.ju.0000154610.81916.81] [Citation(s) in RCA: 113] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
PURPOSE Pretreatment risk assessment models facilitate more appropriate selection of treatment for prostate cancer. However, men with high risk disease remain a challenge with significant potential for primary treatment failure. We characterize patterns of treatment for high risk prostate cancer in a community based cohort. MATERIALS AND METHODS In the Cancer of the Prostate Strategic Urological Research Endeavor (CaPSURE) database, a longitudinal disease registry of men with prostate cancer, we identified those with nonmetastatic, high risk disease based on T stage, tumor grade and serum prostate specific antigen (PSA). Differences in primary treatment, and the use of neoadjuvant and adjuvant therapy in patients at low, intermediate and high risk were assessed. In the high risk cohort predictors of the type of primary treatment, and the use of neoadjuvant and adjuvant androgen therapy were identified. RESULTS Of the cancers 34%, 40% and 26% were low, intermediate and high risk, respectively. Differences in primary treatment type among the 3 risk groups were statistically significant (p <0.0001) with increasing external beam radiation therapy and androgen deprivation, and decreased surgery, brachytherapy and surveillance in men with high risk cancers. In this group older age, higher PSA and nonprivate insurance were associated with decreased use of radical prostatectomy. More than half of the men at high risk receiving radiation therapy also received androgen deprivation, which was significantly higher than in the low and intermediate risk groups (p <0.0001). Factors associated with androgen deprivation in high risk disease were primary therapy, PSA, Gleason sum, T stage, body mass index, insurance status and ethnicity. PSA and Gleason sum were the primary determinants of adjuvant radiation after prostatectomy. CONCLUSIONS Men with high risk but nonmetastatic prostate cancer are more likely to receive radiation therapy as well as androgen deprivation with the latter as primary therapy or in conjunction with local treatment. These data stress the importance of pretreatment risk stratification, education regarding appropriate combinations of local and systemic therapies, and the consideration of novel clinical trials in patients at higher risk.
Collapse
Affiliation(s)
- Maxwell V Meng
- Department of Urology, Program in Urologic Oncology, Urologic Outcomes Research Group, University of California-San Francisco Cancer Center, University of California-San Francisco, San Francisco, California 94115-1711, USA.
| | | | | | | | | |
Collapse
|
48
|
|
49
|
Pucar D, Koutcher JA, Shah A, Dyke JP, Schwartz L, Thaler H, Kurhanewicz J, Scardino PT, Kelly WK, Hricak H, Zakian KL. Preliminary assessment of magnetic resonance spectroscopic imaging in predicting treatment outcome in patients with prostate cancer at high risk for relapse. ACTA ACUST UNITED AC 2005; 3:174-81. [PMID: 15636684 DOI: 10.3816/cgc.2004.n.028] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
The purpose of the study was to determine whether 3D proton magnetic resonance spectroscopic imaging (MRSI) can predict treatment outcome in high risk patients with prostate cancer. Endorectal magnetic resonance imaging (MRI) and 1H-MRSI were performed in 16 patients with prostate cancer who were considered high risk because of clinical stage T3-4, Gleason score>/=8, and/or prostate-specific antigen (PSA) level>20 ng/mL. Patients were treated with chemotherapy/hormone therapy, underwent radical prostatectomy (RP) or radiation therapy, and were followed for PSA relapse (follow-up, 19-43 months). The ratio of choline plus creatine to citrate was used to localize peripheral zone cancer. An MRSI risk score on a scale of 0-3 was derived from the volume and degree of metabolic abnormality. Magnetic resonance spectroscopic imaging risk score, MRI tumor/node (TN) stage, clinical stage, Gleason score, and PSA were used as predictors of pathologic stage in patients treated with RP (n=10) and PSA relapse in all patients. Magnetic resonance imaging TN stage (P<0.01) and MRSI risk score (P<0.05) correlated with pathologic stage, but clinical stage did not (P=0.35). Magnetic resonance imaging TN stage was the only significant predictor of PSA relapse in the univariate analysis (P<0.05). Although the MRSI risk score did not reach significance (P=0.13), 6 patients with a score<0.9 were relapse-free, whereas 7 of 10 patients with a score>0.9 relapsed. Magnetic resonance imaging and MRSI risk assessments agreed in 15 of 16 patients. These preliminary results suggest that tumor metabolic assessment may indicate treatment outcome in high-risk patients with prostate cancer. Although MRSI did not provide added prognostic value to MRI in this small number of patients, MRSI might increase the confidence of the clinician in assessing risk on MRI by contributing supporting metabolic data.
Collapse
Affiliation(s)
- Darko Pucar
- Department of Medical Physics, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Sciarra A, Cardi A, Salvatori G, D'Eramo G, Mariotti G, Di Silverio F. Which patients with prostate cancer are actually candidates for hormone therapy? Int Braz J Urol 2005; 30:455-65. [PMID: 15663802 DOI: 10.1590/s1677-55382004000600002] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2004] [Accepted: 09/30/2004] [Indexed: 11/22/2022] Open
Abstract
In this article, we will try to address the following aspects: which factors are responsible of the introduction of new candidates for hormone therapy in prostate cancer, who are actually candidates for hormone therapy, classifying them on the basis of the stage of the disease, and which treatment modalities can be proposed for each candidate. Since the introduction of hormone therapy for the treatment of prostate cancer, there has been a debate about the optimal timing of hormone therapy. A modification in the timing of hormone therapy produced new candidates for hormone manipulation. In particular, the use of hormone treatment for younger patients, longer periods and early prostate cancer, absolutely requires a whole re-evaluation of which therapy is indicated and it may produce new problems such as higher risk of over-treatment, need of a better evaluation of quality of life in younger patients and the research for better tolerated therapies. Therapies that resist for longer periods without the production of a hormone-refractory disease are also required.
Collapse
|